Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05031494 is registered in ClinicalTrials.gov with Eucure (Beijing) Biopharma Co., Ltd as lead sponsor.

NCT NCT05031494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05031494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor
Eucure (Beijing) Biopharma Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2021
Completion date
August 16, 2023
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, pancreatic ductal adenocarcinoma